L
Lluís Puig
Researcher at Autonomous University of Barcelona
Publications - 510
Citations - 16811
Lluís Puig is an academic researcher from Autonomous University of Barcelona. The author has contributed to research in topics: Psoriasis & Medicine. The author has an hindex of 56, co-authored 427 publications receiving 13381 citations. Previous affiliations of Lluís Puig include Jikei University School of Medicine & Pompeu Fabra University.
Papers
More filters
Journal ArticleDOI
Erythema Gyratum Atrophicans Transiens Neonatale: A Variant of Cutaneous Neonatal Lupus Erythematosus
TL;DR: The differential diagnosis of any annular erythema in the newborn requires careful clinicopathologic evalu ation, with direct immunofluorescence studies and determination of anti‐Ro/ SS‐A, anti‐La/SS‐B.
Journal ArticleDOI
Effect of secukinumab on quality of life and psoriasis-related symptoms: A comparative analysis versus ustekinumab from the CLEAR 52-week study
Lluís Puig,Matthias Augustin,Andrew Blauvelt,Alice B. Gottlieb,Ronald Vender,Neil J. Korman,Diamant Thaçi,Yang Zhao,Isabelle Gilloteau,Bintu Sherif,Nicole Williams,Adriana Guana,Mark Lebwohl +12 more
TL;DR: This patient‐reported outcome analysis confirms greater and sustained benefits of secuk inumab versus those of ustekinumab treatment on patients' lives.
Journal ArticleDOI
Allergic contact dermatitis due to ranitidine.
Journal ArticleDOI
Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial
Diamant Thaçi,Bruce Strober,Kenneth B. Gordon,Peter Foley,Melinda Gooderham,Akimichi Morita,Kim A. Papp,Lluís Puig,M. Alan Menter,Matthew J. Colombo,Yedid Elbez,Renata Kisa,J Ye,Andrew Napoli,Lan Wei,Subhashis Banerjee,Joseph F. Merola,Alice B. Gottlieb +17 more
TL;DR: Deucravacitinib is an oral, selective tyrosine kinase 2 inhibitor that demonstrated therapeutic benefit in a Phase 2 clinical trial of adults with moderate to severe plaque psoriasis as mentioned in this paper .
Journal ArticleDOI
The safety of ustekinumab for the treatment of psoriatic arthritis.
TL;DR: In clinical practice, ustekinumab is generally a well-tolerated treatment, and the safety profile in psoriatic arthritis is similar to that reported in plaque psoriasis.